Aaron R. Mangold, M.D.

The purpose of this study is to evaluate a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

The purpose of this study is to determine the safety and efficacy of brepocitinib (a tyrosine kinase [TYK]2/Janus kinase [JAK]1 inhibitor) in adult participants with active, moderate to severe lichen planopilaris (LPP).

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. 

The primary purpose of this study is to assess the efficacy and safety of ruxolitinib 1.5% cream BID in participants with mild to moderate HS (Hurley Stage I or II) with no draining tunnels.

The purpose of this study is to evaluate the effectiveness of PF-06823859 in reducing muscle symptoms in adult participants with active Dermatomyositis (DM) and adult participants with active Polymyositis (PM).

The purpose of this study is to determine the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma.  

The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

The purpose of this study is to identify the incidence and prevalence of inflammatory arthritis in patients with Hidradenitis Suppurativa (HS) and compare them with those in patients with psoriasis through implementing a routine screening. Identifying the incidence and prevalence of this comorbidity has the potential to increase awareness across the specialties of rheumatology and comorbid diseases.

The aims of this study are to determine the frequency, severity, and duration of symptoms of arthritis in patients with HS and compare them with those in patients with psoriasis, to determine the association between inflammatory arthritis and disease flare-ups/severity in HS, to investigate impact of inflammatory arthritis on the quality of life and mental health of HS patients, and to determine the association of inflammatory arthritis in the context of other systemic inflammatory diseases (inflammatory bowel disease (IBD), rheumatoid arthritis (RA), etc.) in these two-patient population of psoriasis and HS.

The purpose of this study is to investigate if benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps.

This study is seeking participants who:

* have moderate or severe HS
* have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose.

Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone.

The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.

The purpose of this study is to identify the incidence and prevalence of inflammatory arthritis in patients with Hidradenitis Suppurativa (HS) and compare them with those in patients with psoriasis through implementing a routine screening. Identifying the incidence and prevalence of this comorbidity has the potential to increase awareness across the specialties of rheumatology and comorbid diseases.

The aims of this study are to determine the frequency, severity, and duration of symptoms of arthritis in patients with HS and compare them with those in patients with psoriasis, to determine the association between inflammatory arthritis and disease flare-ups/severity in HS, to investigate impact of inflammatory arthritis on the quality of life and mental health of HS patients, and to determine the association of inflammatory arthritis in the context of other systemic inflammatory diseases (inflammatory bowel disease (IBD), rheumatoid arthritis (RA), etc.) in these two-patient population of psoriasis and HS.

The purpose of this study is to evaluate the efficacy of brepocitinib for the treatment of skin-predominant dermatomyositis based on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity (-A) score after 12 weeks of brepocitinib administration once daily (QD), in comparison to baseline.

The purpose of this study is to assess the long-term safety, tolerability, and effectiveness of secukinumab over ustekinumab for the treatment of patients who have moderate to severe plaque psoriasis.

The purpose of this study is to evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD

The purpose of this study is to compare the number of new biopsy confirmed Basal Cell Carcionomas (BCCs) that
develop on the face over a 6-month period between the treatment arms, active and placebo.
 

The primary purpose of this study is to demonstrate that Dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP). 

A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti‑TNF Therapy. Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects Naïve to Biologic Therapy.

The purpose of this study is to assess the safety, effectiveness, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE), and to assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.  

The purpose of this study is to evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.  

The purpose of this study is to establish the effectiveness of ruxolitinib 1.5% cream BID (twice daily) in participants with cutaneous lichen planus (LP).

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

The purpose of this study is to evaluate the effectiveness of PF-06650833, PF-06700841, and PF-06826647 vs placebo in participants with Hidradenitis Suppurativa (HS) as assessed by Hidradenitis Suppurativa Clinical Response (HiSCR).

The purpose of this study is to evaluate the effect of brensocatib compared with placebo. 

The primary purpose of this study is to assess the effectiveness of REGN3500 monotherapy in atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD.

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.

The purpose of this study is to determine the effetiveness and safety of brepocitinib (a tyrosine kinase [TYK] 2/Janus kinase [JAK] 1 inhibitor) in patients with dermatomyositis.

The purpose of this study is to evaluate the effectiveness and safety of orally-administered enpatoran in idiopathic inflammatory myopathies, specifically Dermatomyositis (DM) and Polymyositis (PM) patients in a randomized, double-blind, placebo-controlled (DBPC) 24-week study.

This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may kill cancer cells.

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis.

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 1 year from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.

The purpose of this study is to evaluate the effectiveness of PCS499 at 6 Months in treating ulcerations in patients who have necrobiosis lipoidica.

The primary purpose of this study is to evaluate the effectiveness of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).

The primary purpose of this study is to demonstrate the effectiveness of efgartigimod PH20 SC compared to placebo in the treatment of patients with Pemphigus Vulgaris (PV).  

The purpose of this two-part study is to confirm the dose of nomacopan for Part A and sample size for Part B, and also rank the order of secondary endpoints for Part B, to evaluate the safety of nomacopan with adjunct OCS in Parts A and B, to test drug effectiveness and particularly whether treatment with nomacopan and adjunct oral corticosteroid (OCS), with steroid tapered (between weeks 2 and 24) according to disease response, leads to a higher proportion of patients in complete disease remission than treatment with placebo and adjunct OCS, and to examine whether there is a reduction in cumulative OCS use and fewer steroid related adverse events in the nomacopan than the placebo arm in Part B.

The primary purpose of this study is to assess the safety of extended treatment and retreatment with efgartigimod PH20 SC in patients with Pemphigus Vulgaris (PV) or Pemphigus Foliaceus (PF).

The purpose of this study is to evaluate the safety and efficacy of Baricitinib (LY3009104) in cutaneous LP as assessed by the change in Physician Global Assessment (PGA) of skin, oral mucosa, and hair, Body Surface Area (BSA), Index Treatment and Control Lesion by Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) score, Pruritus Visual Analog Scale (VAS), Verbal Rating Scale (VRS), Pruritus Numerical Rating Scale (NRS), and Skindex-16. To predict responses through the identification of unique biomarkers of LP at week 0 and utilizing RNA sequencing on responsive and non-responsive tissue at week 2. 

The purpose of this study is to determine the frequency with which Mayo fragrance patch test allergic patients co-react to commercially available, commonly used fragrance ingredients/components, fragrance oils and detergents.

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Lichen Planopilaris as assessed by the change in Physician Global Assessment (PGA) of skin, oral mucosa, and hair, LPPAI, and mean follicular density, and to predict responses through the identification of unique biomarkers of LPP at week 0 and utilizing single-cell RNA sequencing.

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

The purpose of this study is to use an online educational platform to teach patients about their risk of melanoma and how to prevent it. In the same online platform, there will be surveys to test pre and post knowledge and gather sun behavior information. Patients will be reached by email. 

The purpose of this study is to establish a mobile phone-based store and forward technology to improve patient access to dermatology care and increase primary care provider confidence and satisfaction in the management of dermatologic conditions.

The purpose of this study is to evaluate the effects of topical INCB018424 PHOSPHATE CREAM 1.5% twice daily on lesions of cutaneous lichen planus (LP).

Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

The purpose of this study is to assess the knowledge base and standard of care of common dermatologic conditions and procedures seen and performed by primary care physicians at Mayo Clinic Arizona -Develop and optimize online learning modules of key areas in dermatology -To determine the success of online education modules.

The main purpose of this study is to evaluate the effectiveness and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.

The purpose of this study is to evaluate the safety and effectiveness of Ruxolitinib cream in Necrobiosis Lipoidica (NL) as assessed by the change in NL score (0-12) of the index treatment lesions, Pruritus NRS, Skindex-16, Physician Global Assessment (PGA), and BSA. 

The purpose of this study is to predict responses through the identification of unique biomarkers of DM utilizing bulk, single-cell and spatial RNA sequencing.

The primary purpose of this study is to evaluate the effectiveness and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The study will compare the effects of cobomarsen to vorinostat, a drug that has been approved for the treatment of CTCL in the United States and several other countries.

The purpose of this study is to create a cutaneous lymphoma tissue repository. This is a highly significant first step in collecting specimens for future analysis to understand the underlying drivers of disease.